We are live on
!
Find out more
MACM
March Altus Capital Management Portfolio holdings
AUM
$16M
1-Year Est. Return
18.92%
This Fund
S&P 500
This Quarter
Est. Return
+16.76%
1 Year Est. Return
+18.92%
3 Year Est. Return
+155.68%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$219M
AUM Growth
-$32.3M
(-13%)
Cap. Flow
-$58.2M
Cap. Flow
% of AUM
-26.56%
Top 10 Holdings %
Top 10 Hldgs %
58.97%
Holding
34
New
9
Increased
2
Reduced
10
Closed
11
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amgen
AMGN
|
+$12.6M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
+$11.6M |
| 3 |
MDCO
Medicines Co
MDCO
|
+$10.8M |
| 4 |
Align Technology
ALGN
|
+$10.4M |
| 5 |
Humana
HUM
|
+$8.41M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AEGR
Aegerion Pharmaceuticals
AEGR
|
+$13.5M |
| 2 |
Johnson & Johnson
JNJ
|
+$13M |
| 3 |
ZLTQ
ZELTIQ Aesthetics, Inc.
ZLTQ
|
+$12.2M |
| 4 |
Biogen
BIIB
|
+$10.9M |
| 5 |
ACOR
Acorda Therapeutics
ACOR
|
+$10.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 97.88% |
| 2 | Miscellaneous | 2.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
United Therapeutics
UTHR
$21.3B
| $14.9M | 6.81% |
115,077
-54,475
| -32% | -$7.02M |
|
2
DexCom
DXCM
$31.3B
| $14.7M | 6.72% |
1,068,304
-469,908
| -31% | -$5.75M |
|
|
MNK
3
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
| $14.4M | 6.56% |
145,071
-51,105
| -26% | -$4.7M |
|
4
Universal Health Services
UHS
$10.3B
| $13.7M | 6.25% |
122,904
+30,097
| +32% | +$3.16M |
|
|
5
Amgen
AMGN
$204B
| $12.8M | 5.86% |
+80,600
| New | +$12.6M |
|
|
ALXN
6
DELISTED
Alexion Pharmaceuticals
ALXN
| $12.2M | 5.57% |
65,960
-1,120
| -2% | -$208K |
|
|
7
Regeneron Pharmaceuticals
REGN
$80.5B
| $12.2M | 5.55% |
+29,620
| New | +$11.6M |
|
|
MDCO
8
DELISTED
Medicines Co
MDCO
| $12.1M | 5.51% |
+435,986
| New | +$10.8M |
|
9
West Pharmaceutical
WST
$24.4B
| $11.2M | 5.13% |
210,910
+72,112
| +52% | +$3.61M |
|
|
10
Align Technology
ALGN
$10.7B
| $11M | 5.01% |
+196,368
| New | +$10.4M |
|
11
Eli Lilly
LLY
$994B
| $10.7M | 4.9% |
155,417
-46,031
| -23% | -$3.11M |
|
|
UAM
12
DELISTED
Universal American Corp
UAM
| $10.5M | 4.78% |
1,128,043
-985
| -0.1% | -$8.56K |
|
|
WCG
13
DELISTED
Wellcare Health Plans, Inc.
WCG
| $9.67M | 4.42% |
+117,823
| New | +$8.21M |
|
|
14
Humana
HUM
$49.2B
| $8.85M | 4.04% |
+61,581
| New | +$8.41M |
|
|
CYNO
15
DELISTED
Cynosure, Inc. Class A
CYNO
| $8.66M | 3.95% |
+315,717
| New | +$8.02M |
|
|
SEM
16
DELISTED
Select Medical
SEM
| $7.83M | 3.57% |
1,008,652
-287,126
| -22% | -$2.09M |
|
|
AVDL
17
DELISTED
Avadel Pharmaceuticals
AVDL
| $6.76M | 3.09% |
+394,897
| New | +$5.64M |
|
|
ENZY
18
DELISTED
Enzymotec Ltd
ENZY
| $5.13M | 2.34% |
681,778
| – | – |
|
|
AMAG
19
DELISTED
AMAG Pharmaceuticals
AMAG
| $4.82M | 2.2% |
113,079
-225,644
| -67% | -$8.15M |
|
|
UAM
20
CALL
DELISTED
Universal American Corp
UAM
| $4.64M | 2.12% |
500,000
| – | – |
|
21
Zoetis
ZTS
$30.2B
| $4.55M | 2.08% |
105,822
-184,692
| -64% | -$7.49M |
|
22
Encompass Health
EHC
$12B
| $4.15M | 1.89% |
135,611
-307,663
| -69% | -$9.59M |
|
23
Incyte
INCY
$24.6B
| $3.6M | 1.64% |
+49,217
| New | +$3.22M |
|
|
24
Biogen
BIIB
$32.1B
| – | – |
-32,986
| Closed | -$10.9M |
|
25
Cencora
COR
$61.4B
| – | – |
-127,799
| Closed | -$9.88M |
|
Similar funds
IC
PA
GMIM
JHWCP
SMPIAI
NCMG
CAD
GPI
March Altus Capital Management's Q4 2014 Portfolio in Review
As of Q4 2014, March Altus Capital Management held 34 positions worth $219M, down 13% from $251M the previous quarter. Its ten largest holdings account for 59% of the portfolio.
March Altus Capital Management withdrew a net $58.2M in Q4 2014, closing 11 positions and reducing 10 holdings. Its most notable exit was Aegerion Pharmaceuticals, an estimated $13.5M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 98% a quarter earlier, followed by Miscellaneous.
Against the trend, March Altus Capital Management opened a new position in Amgen worth $12.8M.
- March Altus Capital Management's largest Q4 2014 buy was Amgen: 80,600 shares worth $12.8M.
- March Altus Capital Management added most to West Pharmaceutical in Q4 2014, an estimated $3.61M increase.
- March Altus Capital Management's biggest Q4 2014 reduction was Encompass Health, cutting an estimated $9.59M.
- March Altus Capital Management fully exited Aegerion Pharmaceuticals in Q4 2014, selling an estimated $13.5M.
- March Altus Capital Management's ten largest holdings make up 59% of its $219M portfolio in Q4 2014.
- March Altus Capital Management opened 9 new positions and closed 11 in Q4 2014.
- March Altus Capital Management's portfolio value fell 13% quarter-over-quarter to $219M.
Based on March Altus Capital Management's 13F filing for Q4 2014, filed 17 Feb 2015.